Redeye views the news that Dignitana has been selected as preferred scalp cooling provider by GenesisCare as further proof of concept. The Dignicap Delta has been evaluated during the last 12 months with a positive outcome. The systems' roll-out will be done to the seven medical oncology facilities in Australia, with additional units added in the next two to three years. We see this news as positive and underline the positive outlook for Dignitana in the coming years. We do not expect to make any estimate changes based on this agreement. We reiterate our stronger conviction that we stated after the Q3 report with a motivated value of SEK 15 per share in our Base case.